IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) today commented on a petition filed by Public Citizen yesterday with the U.S. Food and Drug Administration (FDA) suggesting additional label changes and a written communication to physicians regarding botulinum toxin products.
